Stockscreener 앱 받기
1.695
0.88%
-0.015
전일 마감가:
$1.71
열려 있는:
$1.71
하루 거래량:
91,609
Relative Volume:
0.23
시가총액:
$51.37M
수익:
-
순이익/손실:
$-25.94M
주가수익비율:
-1.2283
EPS:
-1.38
순현금흐름:
$-15.79M
1주 성능:
-0.88%
1개월 성능:
-9.36%
6개월 성능:
-11.72%
1년 성능:
-54.80%
1일 변동 폭
$1.66
$1.72
1주일 범위
$1.64
$1.90
52주 변동 폭
$1.40
$4.24
MAIA Biotechnology Inc Stock (MAIA) Company Profile
명칭
MAIA Biotechnology Inc
전화
312 416 8592
주소
444 West Lake Street, Suite 1700, Chicago
MAIA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.695 | 54.77M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.69 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.07 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.63 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.03 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
293.98 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
What analysts say about MAIA Biotechnology Inc. stockGame-changing capital returns - jammulinksnews.com
Is MAIA Biotechnology Inc. a good long term investmentRapid market gains - jammulinksnews.com
MAIA Biotechnology’s 41% decline validates InvestingPro’s overvalued call By Investing.com - Investing.com
What drives MAIA Biotechnology Inc. stock priceExceptional earning trajectories - Autocar Professional
Is MAIA Biotechnology Inc. stock a growth or value playMomentum Swing Watchlist - beatles.ru
MAIA Biotechnology Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
When is the best time to buy MAIA Biotechnology Inc. stockPro Trader Stock Focus - Newser
Maia Biotechnology stock soars after publishing promising preclinical data - Investing.com
MAIA Biotechnology Publishes Promising Preclinical Cancer Data - TipRanks
MAIA Biotechnology publishes preclinical data on cancer drug candidates By Investing.com - Investing.com Canada
Maia Biotechnology stock soars after publishing promising preclinical data By Investing.com - Investing.com Canada
MAIA Biotechnology publishes preclinical data on cancer drug candidates - Investing.com
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy - Business Wire
Why MAIA Biotechnology Inc. stock attracts strong analyst attentionFree Stock Selection - Newser
How MAIA Biotechnology Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
What makes MAIA Biotechnology Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial - Yahoo Finance
MAIA Biotechnology doses first patient in Taiwan for NSCLC trial By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Begins Phase 2 Trial Expansion - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 0.5% – Still a Buy? - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress - BioSpace
Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners - Investing.com
MAIA Biotechnology, Roche Partner for Hard-to-Treat Cancer Therapies - Contract Pharma
MAIA Biotechnology appoints HCC experts to scientific advisory board - Investing.com
MAIA Biotechnology, Roche sign supply agreement for cancer therapies - Yahoo Finance
MAIA Biotechnology partners with Roche for cancer treatment studies By Investing.com - Investing.com South Africa
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise - MarketScreener
MAIA Biotech (MAIA) Partners with Roche for Cancer Treatment Study - GuruFocus
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies - marketscreener.com
MAIA Biotechnology in pact with Roche for cancer treatments - Seeking Alpha
MAIA Biotechnology partners with Roche for cancer treatment studies - Investing.com
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies - BioSpace
MAIA Biotechnology Announces Agreement with Roche - TipRanks
MAIA Biotechnology Inc (MAIA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.44%
자본화:
|
볼륨(24시간):